Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms

Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms

Breast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kin...

Full description

Bibliographic Details
Main Authors: Bin Wang, Rui Li, Shuai Wu, Xin Liu, Jianlin Ren, Jing Li, Kaixin Bi, Yanhong Wang, Hongyan Jia
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
breast cancer
CDK4/6 inhibitors
drug resistance
molecular mechanisms
combination administration
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.651541/full
id doaj-8bfabd0a2358476b88a0a6a8fb02e4eb
record_format Article
spelling doaj-8bfabd0a2358476b88a0a6a8fb02e4eb2021-05-26T06:53:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-05-011110.3389/fonc.2021.651541651541Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular MechanismsBin Wang0Rui Li1Shuai Wu2Xin Liu3Jianlin Ren4Jing Li5Kaixin Bi6Yanhong Wang7Hongyan Jia8Department of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Microbiology and Immunology, Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaBreast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kinases 4/6CDK4/6inhibitors have shown good clinical activity in treating breast cancer. Nevertheless, despite the promising clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitors has limited the benefits of this novel target therapy. In the present review, we provide an overview of the currently known molecular mechanisms of resistance to CDK4/6 inhibitors, and discuss the potential strategies to overcoming drug resistance improving the outcomes for breast cancer patients treated with CDK4/6 inhibitors.https://www.frontiersin.org/articles/10.3389/fonc.2021.651541/fullbreast cancerCDK4/6 inhibitorsdrug resistancemolecular mechanismscombination administration
collection DOAJ
language English
format Article
sources DOAJ
author Bin Wang
Rui Li
Shuai Wu
Xin Liu
Jianlin Ren
Jing Li
Kaixin Bi
Yanhong Wang
Hongyan Jia
spellingShingle Bin Wang
Rui Li
Shuai Wu
Xin Liu
Jianlin Ren
Jing Li
Kaixin Bi
Yanhong Wang
Hongyan Jia
Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
Frontiers in Oncology
breast cancer
CDK4/6 inhibitors
drug resistance
molecular mechanisms
combination administration
author_facet Bin Wang
Rui Li
Shuai Wu
Xin Liu
Jianlin Ren
Jing Li
Kaixin Bi
Yanhong Wang
Hongyan Jia
author_sort Bin Wang
title Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
title_short Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
title_full Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
title_fullStr Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
title_full_unstemmed Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
title_sort breast cancer resistance to cyclin-dependent kinases 4/6 inhibitors: intricacy of the molecular mechanisms
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-05-01
description Breast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kinases 4/6CDK4/6inhibitors have shown good clinical activity in treating breast cancer. Nevertheless, despite the promising clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitors has limited the benefits of this novel target therapy. In the present review, we provide an overview of the currently known molecular mechanisms of resistance to CDK4/6 inhibitors, and discuss the potential strategies to overcoming drug resistance improving the outcomes for breast cancer patients treated with CDK4/6 inhibitors.
topic breast cancer
CDK4/6 inhibitors
drug resistance
molecular mechanisms
combination administration
url https://www.frontiersin.org/articles/10.3389/fonc.2021.651541/full
work_keys_str_mv AT binwang breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms
AT ruili breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms
AT shuaiwu breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms
AT xinliu breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms
AT jianlinren breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms
AT jingli breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms
AT kaixinbi breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms
AT yanhongwang breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms
AT hongyanjia breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms
_version_ 1721426423419240448

Similar Items